Andrej Karpathy 总结过去 5 周医学领域的多项进展：Lilly 三重激动剂 retatrutide 在减脂和全身炎症上达到创纪录水平，RevMed 胰腺癌新药展现前所未有的延长生命能力，PCSK9 基因编辑疗法单次治疗大幅降低 LDL 胆固醇，Mayo 的 AI 辅助放射学显著提升癌症检出率，以及针对转移性实体瘤的新疗法。
This has quietly been a miracle month in medicine.
In the last 5 weeks we’ve got news on:
- retatrutide, the triple agonist GLP-1 from Lilly, basically melting fat and body-wide inflammation at record levels
- RevMed’s new pancreatic cancer drug showing unprecedented abilities to extend life
- small trial of a one-and-done PCSK9 gene editing therapy for slashing LDL cholesterol
- Mayo’s AI-assisted radiology showing vastly improved cancer detection
- this new therapy for metastatic solid tumors
This stuff is at varying levels of evidence. Retatrutide is ~100% on its way, other stuff needs more clinical trial data. But put it together and we’re maybe on the verge of majorly reducing the mortality of heart disease and cancer, the two leading causes of death in America.
This is actually insane. 97% of people taking the standard of care for metastatic solid tumor got worse by seven years. But with lorlatinib, that number was only 45% in the same time! This is an ENORMOUS jump in the quality of cancer care.在 X 查看被引用的帖子
来源：@DKThomp · x.com